中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 35 Issue 3
Mar.  2019
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2019  >  35(3): 592-595

Effect of human liver-derived stem cells in prevention and treatment of alcoholic fatty liver disease in mice

DOI: 10.3969/j.issn.1001-5256.2019.03.027

  • Intractable Hepatic Diseases and Artificial Liver Treatment & Training Center, Beijing Key Laboratory of Liver Failure and Atrificial Liver Treatment and Research, Beijing YouAn Hospital, Capital Medical University

Research funding:

 

  • Published Date: 2019-03-20
    Abstract

  • Objective To investigate the effect of intraperitoneal transplantation of human liver-derived stem cells in the prevention and treatment of alcoholic fatty liver disease in mice. Methods A total of 30 male C57 BL/6 mice were randomly divided into blank control group ( group N) , model control group ( group M) , and stem cell transplantation group ( group S) . The mice in group N were fed a normal diet, and those in the other two groups were fed Lieber-DeCarli alcohol liquid diet; at the same time, the mice in group S were given intraperitoneal transplantation of human liver-derived stem cells twice a week. After six weeks of intervention, body weight and liver index were measured, and the serum levels of alanine aminotransferase ( ALT) , aspartate aminotransferase ( AST) , total bilirubin ( TBil) , total cholesterol ( TC) , triglyceride ( TG) , high-density lipoprotein cholesterol ( HDL-C) , and low-density lipoprotein cholesterol ( LDL-C) were also measured. The levels of TG and non-esterified fatty acid ( NEFA) in the liver were measured, and liver pathological examination and oil red O staining of the liver were performed. One-way ANOVA was used for comparison of continuous data between multiple groups, and the SNK-q test was used for further comparison between two groups. Results There were significant differences in the serum levels of ALT, AST, TG, TC, and HDL-C and the content of TG and NEFA in the liver between the three groups ( F = 66. 94, 7. 15, 8. 02, 18. 64, 3. 86, 23. 14 and 30. 49, all P < 0. 05) , Compared with group N, group M showed significant increases in levels of ALT, AST, and TG in serum and levels of TG and NEFA in liver tissue ( all P < 0. 05) . Group S had significantly lower levels of ALT, AST, and TG in serum and levels of TG and NEFA in liver tissue than group M ( all P < 0. 05) . Liver HE staining and oil red O staining showed that group S had a significantly lower degree of liver steatosis than group M. Conclusion Intraperitoneal transplantation of human liver-derived stem cells has a marked effect in the prevention and treatment of alcoholic fatty liver disease in mice.

     

    • FullText(HTML)
  • loading
    • References(23)
  • [1] Fatty Liver and Alcoholic Liver Disease Study Group of the Chi-nese Liver Disease Association, Chinese Medical Association.Guidelines for prevention and treatment of alcoholic liver dis-ease (revised version 2010) [J]. J Clin Hepatol, 2010, 26 (3) :229-232. (in Chinese) 中华医学会肝病学分会脂肪肝和酒精性肝病学组.酒精性肝病诊疗指南 (2010年修订版) [J].临床肝胆病杂志, 2010, 26 (3) :229-232.
    [2] European Association for the Study of Liver. EASL clinical practi-cal guidelines:Management of alcoholic liver disease[J]. J Hep-atol, 2012, 57 (2) :399-420.
    [3] WARREN KR, MURRAY MM. Alcoholic liver disease and pan-creatitis:Global health problems being addressed by the USNational Institute on Alcohol Abuse and Alcoholism[J]. J Gas-troenterol Hepatol, 2013, 28 (Suppl 1) :4-6.
    [4] O'SHEA RS, DASARATHY S, MCCULLOUGH AJ. Alcoholicliver disease[J]. Hepatology, 2010, 51 (1) :307-328.
    [5] MCCULLOUGH AJ, O'SHEA RS, DASARATHY S. Diagnosisand management of alcoholic liver disease[J]. J Dig Dis, 2011, 12 (4) :257-262.
    [6] FAN JG. Epidemiology of alcoholic and nonalcoholic fatty liverdisease in China[J]. J Gastroenterol Hepatol, 2013, 28 (Sup-pl 1) :11-17.
    [7] AKIYAMA K, CHEN C, WANG D, et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis[J]. Cell Stem Cell, 2012, 10 (5) :544-555.
    [8] KUO TK, HUNG SP, CHUANG CH, et al. Stem cell therapyfor liver disease:Parameters governing the success of usingbone marrow mesenchymal stem cells[J]. Gastroenterology, 2008, 134 (7) :2111-2121.
    [9] ZHANG Z, WANG FS. Stem cell therapies for liver failure andcirrhosis[J]. J Hepatol, 2013, 59 (1) :183-185.
    [10] SPAHR L, LAMBERT JF, RUBBIA-BRANDT L, et al. Granu-locyte-colony stimulating factor induces proliferation of hepat-ic progenitors in alcoholic steatohepatitis:A randomized trial[J]. Hepatology, 2008, 48 (1) :221-229
    [11] AURICH H, SGODDA M, KALTWASSER P, et al. Hepatocytedifferentiation of mesenchymal stem cells from human adiposetissue in vitro promotes hepatic integration in vivo[J]. Gut, 2009, 58 (4) :570-581.
    [12] BI YZ, FAN Z, CHEN DF, et al. Protective effect of intraperito-neal transplantation of human fiver-derived stem cells at dif-ferent times against concanavalin A-induced acute liver injuryin mice[J]. Chin J Hepatol, 2017, 25 (3) :205-210. (inChinese) 毕研贞, 樊增, 陈东风, 等.人肝源性干细胞腹腔移植不同时间对Con A诱导小鼠急性肝损伤保护作用[J].中华肝脏病杂志, 2017, 25 (3) :205-210.
    [13] LOMBARD R, BUZZETTI E, ROCCARINA D, et al. Non-in-vasive assessment of liver fibrosis in patients with alcoholic liv-er disease[J]. World J Gastroenterol, 2015, 21 (39) :11044-11052.
    [14] MANDAL A, GRUPP A, SCHWEDERSKI B, et al. Noninno-cently behaving bridging anions of the widely distributed an-tioxidant ellagic acid in diruthenium complexes[J]. InorgChem, 2015, 54 (20) :10049-10057.
    [15] LIN XX, CHEN D, ZHAO Q, et al. Genetic research on the in-cidence of alcoholic liver disease[J]. Chin J Clin PharmacolTher, 2017, 22 (11) :1309-1314. (in Chinese) 林秀贤, 陈丹, 赵青, 等.影响酒精性肝病发病的遗传学研究进展[J].中国临床药理学与治疗学, 2017, 22 (11) :1309-1314.
    [16] SZABO G. Gut-liver axis in alcoholic liver disease[J]. Gas-troenterology, 2015, 148 (1) :30-36.
    [17] DI CAMPLI C, PISCAGLI AC, PIERELLI L, et al. A human um-bilical cord stem cell rescue therapy in a murine model of toxicliver injury[J]. Dig Liver Dis, 2004, 36 (9) :603-613.
    [18] YANG S, KOTEISH A, LIN H, et al. Oval cells compensate fordamage and replicative senescence of mature hepatocytes inmice with fatty liver disease[J]. Hepatology, 2004, 39 (2) :403-411.
    [19] MARGINI C, VUKOTIC R, BRODOSI L, et al. Bone marrowderived stem cells for the treatment of end-stage liver dis-ease[J]. World J Gastroenterol, 2014, 20 (27) :9098-9105.
    [20] CHEN Q, KHOURY M, LIMMON G, et al. Human fetal hepaticprogenitor cells are distinct from, but closely related to, hema-topoietic stem/progenitor cells[J]. Stem Cells, 2013, 31 (6) :1160-1169.
    [21] PICHARD V, FERRY N. Origin of small hepatocyte-like pro-genitor in retrorsine-treated rats[J]. J Hepatol, 2008, 48 (2) :368-369.
    [22] GERBAL-CHALOIN S, FUNAKOSHI N, CAILLAUD A, et al.Human induced pluripotent stem cells in hepatology:Beyondthe proof of concept[J]. Am J Pathol, 2014, 184 (2) :332-347.
    [23] ENOSAWA S, HORIKAWA R, YAMAMOTO A, et al. Hepato-cyte transplantation using a living donor reduced graft in a ba-by with ornithine transcarbamylase deficiency:A novel sourceof hepatocytes[J]. Liver Tranpl, 2014, 20 (3) :391-393.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1439) PDF downloads(323) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return